December 12, 2017 08:31 AM EST
R&D

Aduro buries an­oth­er can­cer vac­cine af­ter CRS-207 joins the line­up of clin­i­cal dis­as­ters

John Carroll

Editor & Founder

Af­ter stick­ing it out through a par­tial hold and ear­li­er clin­i­cal tri­al set­backs, Aduro $ADRO is fi­nal­ly wash­ing its hands of a can­cer vac­cine that …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Dai­ichi Sankyo finds suc­ces­sor to late R&D ex­ec; Ver­sant, No­var­tis' kid­ney biotech poach­es Sana CBO

A service from the Financial Times